The short answer
Trans women do not go through ovarian menopause, but midlife raises real questions about long-term estradiol. Current guidance does not require stopping gender-affirming estradiol at a particular age. Clinicians often favor transdermal estradiol in midlife because it carries a lower clot risk than oral tablets, and they review heart, bone and cancer screening. Stopping estradiol without other hormones can cause menopause-like symptoms and bone loss. A licensed clinician helps plan doses and routes for you.
No advertising or analytics trackers run on Specialized Care pages. Reading them is never linked to your identity. Our privacy pledge
Continuing estradiol as you age
Endocrine Society and WPATH guidance support continuing gender-affirming hormones lifelong when appropriate, with doses adjusted to keep levels in a typical physiologic range. Some women reduce doses with age; decisions are individual.
Your clinician should use your name and pronouns, ask about your body and history without assumptions, and never make care conditional on explaining your identity. You share what is relevant to you.
Choosing a route in midlife
Risk of blood clots rises with age, smoking and some health conditions. Oral estradiol passes through the liver and is linked with higher clot risk than patches or gels. Many clinicians move midlife patients to transdermal estradiol, especially with other risk factors. Ethinyl estradiol is not recommended for gender-affirming therapy.
If estradiol is stopped
Stopping estradiol, for example around surgery or illness, can bring hot flashes, low mood, poor sleep and, over time, bone loss, particularly after orchiectomy. Plans to pause or stop should be made with your clinician.
Screening and long-term health
- Heart health: blood pressure, cholesterol, glucose and smoking support
- Breast screening based on years on estrogen and age, following current guidance
- Prostate checks remain relevant; PSA values may read lower on estrogen
- Bone density screening, especially after orchiectomy or interruptions in hormones
Specialized care pathway
Care that respects your values
A licensed Kindr clinician can review your symptoms and health history, listen to your preferences, and discuss options, including hormone therapy or non-hormonal treatment, when medically appropriate.
Questions, answered
Common questions
Do trans women go through menopause?
+
Not ovarian menopause. Menopause-like symptoms can occur if estradiol is reduced or stopped, especially after orchiectomy.
Should I stop estrogen at 50 or 60?
+
There is no required stopping age. Your clinician reviews dose, route and risk factors over time.
Is a patch safer than pills?
+
Transdermal estradiol is associated with lower clot risk than oral estradiol, which is why many clinicians prefer it in midlife.
Do I still need prostate screening?
+
The prostate remains after gender-affirming surgery, so discuss screening with your clinician. PSA results may be lower on estrogen.
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed October 5, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline (Hembree WC, et al.) (2017) — Journal of Clinical Endocrinology & Metabolism. doi.org/10.1210/jc.2017-01658
- Standards of Care for the Health of Transgender and Gender Diverse People, Version 8 (2022) — World Professional Association for Transgender Health (WPATH). doi.org/10.1080/26895269.2022.2100644
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society (2022) — The Menopause Society. www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
- Osteoporosis to Prevent Fractures: Screening recommendation (2025) — U.S. Preventive Services Task Force. www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
- LGBTQIA+ Health Education Center resources — The Fenway Institute. www.lgbtqiahealtheducation.org